is metformin a glp-1 receptor vs. Agonists: Which Diabetes Medication Right for You? Current Insights, Advantages and Challenges

Diabetologia 36 (8), 741744

Over one year, choosing compounded semaglutide at $189 monthly versus Wegovy at $1,200 monthly saves patients more than $12,600 in out-of-pocket expenses

In 2023, branded obesity drug sales reached $6 billion, and this figure is expected to grow exponentially as demand continues to rise and these medications are used to treat a broader range of diseases

Together, these two pathways produce a broader metabolic response than GLP-1 activation alone, which is why tirzepatide has shown more pronounced effects on body weight and blood sugar control in clinical research compared to GLP-1-only medications